Category: CanFite

Can-Fite Phase 3 RA Program Ready To Start

Can-Fite Biopharma Ltd (NYSEMKT: CANF) is preparing to initiate a Phase 3 study with piclidenoson for the treatment of rheumatoid arthritis (RA) in the second quarter 2017. The Phase 3 study, called ACRobat, will investigate piclidenoson as a first line therapy and potential replacement for the current standard of care, methotrexate (MTX), in newly diagnosed…

JPM Meeting Notes – Can-Fite Biopharma (CANF)

I picked a good day to meet with Can-Fite Biopharma (CANF) because that morning the company announced IRB approval from Hadassah Medical Center and Rabin Medical Center, two leading medical institutions in Israel, to commence patient enrollment in a Phase 2 study of namodenoson (formerly CF102) in the treatment of non-alcoholic fatty liver disease (NAFLD), the precursor…

CanFite’s Piclidenoson Positioned For Successful Phase 3 in Psoriasis

Can-Fite BioPharma Ltd. (NYSEMKT: CANF) announced on November 1, 2016, that the company reached an agreement with the European Medicines Agency (EMA) on the final design of a global pivotal Phase 3 trial for its lead drug candidate, piclidenoson (formerly CF101), in the treatment of psoriasis. Can-Fite intends to initiate the Phase 3 trial in the…

Can-Fite An Emerging NASH Play With CF102

Last week, Allergan plc (AGN) acquired two companies on the same day, both in an effort to strengthen its focus on NASH. Allergan spent $615 million to acquire Tobira Therapeutics, Inc. (TBRA) and $50 million to acquire privately-held Akarna Therapeutics. The acquisition of Tobira gives Allergan cenicriviroc, an oral Phase 3 ready potent inhibitor of the…

Can-Fite Looks Meaningfully Undervalued

On August 26, 2016, Can-Fite BioPharma, Ltd (CANF) provided a financial update for the six month period ending June 30, 2016. The company also provided an update on its pipeline, which I believe remains meaningfully undervalued. Can-Fite’s market capitalization today is a measly $33 million, and roughly one-third of that is cash. Below is a…

CF102: An Important Driver For Can-Fite

CanFite Biopharma Ltd. (CANF) is currently conducting a Phase 2 clinical study with CF102 for the treatment of hepatocellular carcinoma (HCC). The focus of the study is to test CF102, a selective A3 adenosine receptor (A3AR) agonist, as a second-line treatment of advanced HCC in subjects with Child-Pugh B cirrhosis. The 78-patient trial is currently…

Can-Fite’s Piclidenoson Compares Well to JAKs, MTX in RA

Last week, Gilead Sciences entered into a global partnership for the development and commercialization of filgotinib, a JAK1-selective inhibitor for inflammatory conditions, with Galapagos NV. Galapagos will receive an upfront payment of $725 million consisting of a cash license fee of $300 million and a $425 million equity investment. In addition, Galapagos is eligible for payments up to $1.35…